Literature DB >> 2430019

Alterations in the amino-terminal third of mouse interleukin 2: effects on biological activity and immunoreactivity.

S M Zurawski, T R Mosmann, M Benedik, G Zurawski.   

Abstract

In this report, we describe plasmids that direct the expression of active mouse interleukin 2 (mIL 2) in Escherichia coli, and the use of this expression system to perform a mutational analysis of the N-terminal region of the mIL 2 protein. We found that the N-terminus was tolerant to the addition of a few amino acids, and even the addition of 20 amino acids resulted in only a modest decrease in activity of the protein. The bioactivity of mIL 2 as defined by its ability to sustain the proliferation of cloned T cells was also only minimally affected by deletion of up to 13 N-terminal amino acids, or of the entire poly-GLN stretch (amino acids 15-26). Deletion of the 30 N-terminal amino acids drastically reduced but did not abolish activity. Deletion of the 41 N-terminal amino acids completely abolished activity, whereas certain changes in the initial 37 amino acids drastically reduced the biological activity of the protein. We also analyzed the immunoreactivity of the mutant proteins with the anti-IL 2 monoclonal antibodies S4B6 and DMS-1. This analysis showed that the determinant recognized by S4B6 required that the N-terminal mIL 2 amino acids 26-45 be intact, whereas the DMS-1 determinant was located to the C-terminal side of amino acid 46.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  {gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells.

Authors:  Jena D French; Christina L Roark; Willi K Born; Rebecca L O'brien
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

2.  Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.

Authors:  Zulmarie Perez Horta; Swetha Saseedhar; Alexander L Rakhmilevich; Lakeesha Carmichael; Jacquelyn A Hank; Margaret Boyden; Stephen D Gillies; Paul M Sondel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

3.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

4.  In vivo induction of IgG anti-DNA antibody by autoreactive mixed haplotype A beta z/A alpha d MHC class II molecule-specific CD4+ T-cell clones.

Authors:  M Tokushima; S Koarada; S Hirose; Y Gotoh; H Nishimura; T Shirai; K Miyake; M Kimoto
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

5.  Interleukin-2 (IL-2) regulates the accessibility of the IL-2-responsive enhancer in the IL-2 receptor alpha gene to transcription factors.

Authors:  C Rusterholz; P C Henrioud; M Nabholz
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

6.  Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects.

Authors:  Gertrudis Rojas; Yanelys Cabrera Infante; Amaury Pupo; Tania Carmenate
Journal:  MAbs       Date:  2013-11-19       Impact factor: 5.857

7.  Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines.

Authors:  G B Lipford; S Bendigs; K Heeg; H Wagner
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

8.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

Authors:  H Hock; M Dorsch; U Kunzendorf; Z Qin; T Diamantstein; T Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Patterns of cytokine production and proliferation by T lymphocytes differ in mice vaccinated or infected with Schistosoma mansoni.

Authors:  R M Pemberton; L E Smythies; A P Mountford; R A Wilson
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

10.  Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction.

Authors:  S M Zurawski; J L Imler; G Zurawski
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.